Recently, we showed that transgenic mice that oversecrete IL-18 from their epidermal cells spontaneously develop AD-like dermatitis under specific pathogen-free (SPF) conditions, and that the deletion of il18, but not stat6, which encodes a signaling molecule necessary for Th2 and IgE responses, protects against the development of AD (4, 5). This finding suggests that excessive cutaneous IL-18 release is a causative factor for intrinsic-type AD. Recent clinical studies have revealed that IL-18 production levels closely parallel disease severity (6-8). Therefore, it is important to clarify whether, and how, endogenous IL-18 contributes to the development of AD when skin is exposed to natural infectious agents.
IL-18 release is a causative factor for intrinsic-type AD. Recent clinical studies have revealed that IL-18 production levels closely parallel disease severity (6) (7) (8) . Therefore, it is important to clarify whether, and how, endogenous IL-18 contributes to the development of AD when skin is exposed to natural infectious agents.
Although it is well documented that cutaneous infection with Staphylococcus aureus exacerbates clinical AD (1, 3) , the underlying mechanism is not fully understood. Recently, we demonstrated that protein A (SpA), a surface molecule and virulent factor of S. aureus (9) , stimulates mouse epidermal cells to secrete IL-18 (10) . However, cutaneous application of SpA alone did not induce major skin alterations in C57BL͞6 mice, despite the fact that it produced elevated serum levels of IL-18 and IgE (5, 10) . This outcome led us to assume that additional factors are required for the development of AD. Because skin cleansing with detergent aggravates clinical AD (1, 11) , skin barrier destruction seems to be a second important factor in AD development. Inasmuch as NC͞Nga mice, which have a genetically impaired skin barrier due to reduced ceramide production (12) , frequently develop AD-like dermatitis after exposure to mites (13) (14) (15) , we assumed that genetic skin barrier dysfunction was a third prerequisite for the development of AD. Here, we generated an intrinsic AD mouse model by daily application of SpA, after destruction of the skin barrier with a subclinical dose of SDS, a detergent (16) . Neutralizing anti-IL-18 Abs could completely protect against SDS͞SpA-induced AD. Furthermore, il18 Ϫ/Ϫ BALB͞c mice evaded development of AD under SDS͞SpA challenge. Our present results clearly demonstrate the importance of both detergent and SpA for the development of AD and provide insight into the immunopathological bases for AD. These findings also point to a possible therapeutic regimen for intrinsic AD that would target IL-18.
Results
SpA-Induced AD-Like Dermatitis. Daily application of SpA after treatment with a subclinical dose of SDS dose-dependently induced AD-like dermatitis in NC͞Nga mice under SPF conditions (Figs. 1A and 2A). However, application of SpA without prior SDS treatment did not induce any skin alterations (Figs. 1 A and 2 A) , indicating a requirement for both SpA and SDS. Because 4% SDS and 200 g of SpA induced the highest levels of skin alteration in all NC͞Nga mice, we used this combination in our study. The AD score (13) peaked at 4 weeks and then declined gradually, but still to a level higher than basal level (Fig. 1 A) . Thus, NC͞Nga mice are highly susceptible to the combined application of SDS and SpA. BALB͞c mice, although they evaded spontaneous skin alterations under conventional conditions, exhibited dermatitis phenotypically similar to that in NC͞Nga mice, but with much lower AD scores (Fig.  1B) . In BALB͞c mice, the AD score peaked at 2 weeks after application and then declined to the lowest levels equivalent to those in mice treated with SDS alone (Fig. 1B) . Thus, BALB͞c mice are moderately susceptible to combined application of SDS and SpA, whereas C57BL͞6 mice are resistant (Fig. 1C) . Because NC͞Nga mice developed severe and persistent AD-like clinical AD, we used this strain of mouse in our analysis. Sequential treatment with SDS and BSA or ovalbumin instead of SpA did not induce skin alterations in NC͞Nga mice (data not shown), suggesting that SpA does not simply serve as a foreign antigen (Ag). Thus, we found that SDS͞SpA-induced AD depended on genetic predisposition, including skin barrier dysfunction (12) .
Inflammatory Skin Alterations with Mast Cell Accumulation. Histological analyses revealed epidermal hyperplasia (acanthosis) and inflammatory changes in the dermis of the skin sites of SDS͞SpA-treated mice (Fig. 2B) . The dermis was densely infiltrated with various subtypes of leukocytes, including eosinophils and mast cells (Fig. 2B) . Focal accumulations of eosinophils were observed in the s.c. layer (Fig. 2B Inset) . In contrast, mice treated with SDS alone showed only minor skin alteration (Fig. 2B) .
The skin sites showed increased T cell numbers and MHC class II levels (Fig. 2B) , suggesting cutaneous accumulation of IFN-␥ (17). However, mice treated with SDS alone had nearly intact skin (Fig. 2B) .
Plasma histamine levels closely paralleled the degree of mastocytosis observed (Fig. 2 C and D) , indicating the presence of activated mast cells. However, serum levels of IgE were not elevated (Fig. 2E) . Collectively, these results indicated that SDS͞SpA-induced dermatitis is a good intrinsic animal model for AD and suggested that IgE is not principally involved in the development of this dermatitis.
Differentiation Toward Super T Helper Type 1 (Th1) Cells Producing Th1
Cytokine, IL-3, and IL-13, but Not IL-4. To address the mechanism underlying the up-regulated MHC class II expression, we investigated whether CD4 ϩ T cells differentiated toward Th1 cells. CD4 ϩ T cells from the regional lymph nodes (LNs) of treated mice at days 1 and 2 produced larger amounts of IFN-␥ than did those from untreated mice (Fig. 3A) . The cells produced basal levels of IL-4 and IL-13, indicating rapid differentiation toward Th1 cells. Intriguingly, CD4 ϩ T cells from mice treated for 7 days and longer gained the capacity to produce much larger amounts of IL-13 and IL-3 as well (Fig. 3A) , indicating that the CD4 ϩ T cells further differentiate into the unique cells that can produce IFN-␥, IL-3, and IL-13, but not IL-4. We propose to designate this subpopulation as ''super Th1 cells'' with regard to their unique potential to produce both Th1-and Th2-related proinflammatory cytokines, each of which is involved in various inflammatory tissue diseases (17) (18) (19) (20) . In contrast, CD4 ϩ LN cells from SDS-treated mice showed a simple and moderate shift to Th1 cells (Fig. 3A) , as was also the case for CD4 ϩ LN cells from ovalbumin͞SDS-treated mice that had no apparent dermatitis (data not shown). These results clearly indicate that the regional LN cells develop toward super Th1 cells after SDS͞SpA application and suggest that the Th1-driving condition attainable with SDS treatment was insufficient for the development of AD. Next, we investigated whether IL-12 and IL-18, prototype cytokines for Th1 cell development (21) , are accumulated in treated mice. Regional LNs expressed il12 after SDS͞SpA challenge (Fig.  3B ). Intriguingly, SDS by itself can induce il12 expression (Fig. 3B) , indicating the importance of SDS for IL-12 production. Consistent with our previous report (10) , in NC͞Nga (Fig. 3C) , BALB͞c, and C57BL͞6 mice (data not shown), IL-18 accumulated in the circulation after application of SDS͞SpA but not SDS alone. 
Rapid Induction of IFN-␥, IL-13, IL-3, and Th1 Chemokines in the Skin
Sites of Treated Mice. It is important to note that the treated skin sites quickly began to express the super Th1-associated cytokines and chemokines required for the recruitment of super Th1 cells (23, 24) . We measured levels of these cytokines in the skin site homogenates. Concentrations of IFN-␥, IL-13, and IL-3, but not IL-4, were increased (Fig. 5A) , indicating that the super Th1 cells are recruited and produce these cytokines in vivo. (Fig. 5 A and B) , which can recruit various subtypes of leukocytes, including mast cells and eosinophils. This change was also the case for cxcl 10 (ip10), cxcl 11 (i-tac), and cxcl2, which can recruit macrophages, T cells, and neutrophils (Fig. 5B) . However, treatment with SDS alone did not induce these chemokine messages (data not shown). These results indicated the importance of SpA for induction of the expression of chemokines.
Because IL-13 is a potent stimulus for CCL11 production (25),
we investigated possible involvement of IL-13 in the elevated CCL11 expression. Treatment with IL-13 antagonist inhibited the elevation of cutaneous CCL11 (Fig. 5C ), indicating that IL-13 is required for the production of CCL11.
IL-18 Induction of Chemokine Receptor Expressions on Super Th1 Cells.
Next, we investigated the mechanism underlying the recruitment of super Th1 cells into the skin sites. Because CXCR3 and CCR5 recognize CXCL10͞CXCL11 and CCL3͞CCL4͞CCL5, respectively, we analyzed CXCR3 and CCR5 expression on the regional LN CD4 ϩ cells. Both CXCR3 and CCR5 expressions were induced on the LN CD4 ϩ cells after SDS͞SpA application (Fig. 6 ). We then examined the possible involvement of IL-18 in these chemokine receptor inductions. IL-18 blockade prevented induction of CXCR3 and CCR5 (Fig. 6) , indicating the requirement of IL-18 for CXCR3 and CCR5 inductions on super Th1 cells.
Contribution of Endogenous IL-18 to the Development of AD.
We tested whether endogenous IL-18 is required for the development of SDS͞SpA-induced AD. Mice treated with neutralizing anti-IL-18 had profoundly reduced AD scores, with little epidermal hyperplasia; little infiltration with T cells, eosinophils, and neutrophils; and basal levels of mast cells and MHC class II ( Fig. 7 A and  B) . To formally establish the essential role of endogenous IL-18, we applied SDS͞SpA to il18 Ϫ/Ϫ BALB͞c mice. Wild-type BALB͞c mice exhibited AD-associated histological changes resembling those in NC͞Nga mice, whereas il18 Ϫ/Ϫ BALB͞c mice were nearly free from these changes (Fig. 7C) , again pointing to IL-18 as a causative factor. These results indicated that endogenous IL-18 is essential for the development of SDS͞SpA-induced AD.
Involvement of IL-3 in the Induction of Cutaneous Mastocytosis.
Because differentiation toward Th1 cells precedes differentiation toward super Th1 cells (Fig. 3A) and fundamentally requires IFN-␥ (17), we investigated the role of IFN-␥. Treatment with neutralizing anti-IFN-␥ protected against the development of AD concomitant with inhibition of elevated MHC class II expression (Fig. 7 A and  B) , indicating the requirement of IFN-␥ for AD development. To investigate how super Th1 cells are involved, we examined the roles of cytokines produced by the super Th1 cells but poorly by Th1 cells. Although treatment with IL-13 antagonist profoundly inhibited the elevation of CCL11 (Fig. 5C ), this treatment did not reduce the AD scores until day 14 (Fig. 7A Inset) , indicating a minor role for IL-13. Because IL-3 induces mast cell proliferation͞activation (20) synergistically with IL-18 (26), we investigated the possible involvement of IL-3. Blockade of IL-13 profoundly inhibited mastocytosis (Fig.  7D) and substantially protected against AD development (Fig. 7 A  and B) . On the basis of all our observations, we conclude that super Th1 cells contribute to the development of AD at least partly by producing IL-3 in response to IL-18.
Discussion
We generated an intrinsic AD mouse model by the application of detergent and subsequently SpA. SDS treatment induced the expression of IL-12, and possibly other cytokines such as IL-23. Topical application of SpA induces the release of IL-18 from keratinocytes. We have provided evidence that IL-18 contributes to intrinsic AD development by inducing and activating super Th1 cells that have the potential to produce IFN-␥, IL-13, and IL-3.
Th1 responses negatively regulate Th2 responses, and vice versa. Theoretically, AD might be classified into two types: Th1 and Th2. However, individual AD patients often have mixed-type immunity (3). As in clinical AD, NC͞Nga mice can develop Th1, Th2, or mixed-type AD. The mice develop Th2-type AD when kept under conventional conditions (13, 14) ; however, they show mixed-type AD after application of SDS͞SpA under SPF conditions. In the strict sense, our SDS͞SpA-induced AD model can be classified as a super Th1 type (Figs. 3A and 4) . Therefore, it is intriguing to note that this super Th1 cell subset alone may explain the complicated immunopathology of some types of clinical AD.
Coproduction of IL-13 and IFN-␥ is a hallmark for certain types of clinical AD. Indeed, lymphocytes from intrinsic AD patients produce greater amounts of IFN-␥ and IL-13 than those from healthy individuals (27) . There are two possible explanations for this outcome. One is that these patients have both Th1 and Th2 cells. Alternatively, the patients may have super Th1 cells. It is quite important to distinguish the latter from the former. Our present results suggest that susceptibility to intrinsic AD is at least partly determined by the intrinsic nature of T lymphocytes to preferentially develop into super Th1 cells. In fact, highly susceptible (NC͞Nga) and moderately susceptible (BALB͞c) mice showed robust and moderate differentiation toward super Th1 cells, respectively (Fig. 4B) , whereas resistant C57BL͞6 mice failed to develop super Th1 cells (data not shown). Notably, in both highly and moderately susceptible strains, IL-18 is commonly essential for the development of AD (Fig. 7) . For patients who have predominantly super Th1 cells, a treatment targeting IL-18 might be very beneficial.
The results of our present study provide evidence that a Th1-skewing milieu can induce allergic inflammatory diseases by differentiating naive CD4 ϩ T cells into super Th1 cells, in collaboration with IL-18. Although they are a major effector cell population involved in IgE-mediated allergic inflammatory diseases, mast cells can be activated by IL-3 and IL-18 in the absence of crosslinkage of their FcRI (20, (28) (29) (30) . Super Th1 cells can be involved in dermal mastocytosis through production of IL-3 in response to Ag and IL-18 (Figs. 3A, 4, 5A, and 7) . Thus, it might be IL-3 that links the Th1-driving circumstances to mast cell involvement in allergic inflammatory diseases.
Super Th1 cells characteristically produce IL-13, a central effector cytokine for the development of inflammatory tissue diseases such as bronchial asthma (18, 31-33) . However, IL-13 is not intensely involved in the development of SDS͞SpA-induced AD, at least in its acute phase (Fig. 7A) . IL-13 is a potent stimulator and activator of transforming growth factor ␤1, a fibrogenic cytokine (31) . Therefore, it is plausible that IL-13 produced by super Th1 cells is involved in the late-occurring dermal fibrosis of SDS͞SpA-induced AD.
SDS͞SpA-treated mice showed major clinical features of AD, indicating the suitability of SDS͞SpA-induced dermatitis as an AD model. Furthermore, skin lesions of SDS͞SpA-treated mice closely resemble those of clinical AD in terms of dense infiltration of eosinophils and mast cells (3, 34) and elevated histamine levels (35) . SDS͞SpA-treated mice showed little increase in serum IgE (Fig.  1E) , suggesting that our model characterizes an intrinsic AD. Although it is important to know that dermal mastocytosis and elevated histamine levels, both of which are major features of this model, are more prominent in clinical intrinsic AD when compared with extrinsic AD, no appropriate clinical reports properly address this issue. Further clinical studies are needed to determine whether this model represents an intrinsic AD in the strict sense.
Notably, SpA cannot be replaced by conventional protein Ags (data not shown), suggesting that SpA might perform several functions that ovalbumin or BSA cannot. First, SpA can stimulate keratinocytes to release IL-18 (10). Second, SpA seems to directly cause rapid expression of chemokines in the skin sites (Fig. 5) , as it does in the respiratory tract (9) . Thus, SpA can function as a professional AD-inducing protein in certain situations, which presents the possibility that molecules that can induce IL-18 and chemokine release from epidermal cells might function as an intrinsic AD-inducing factor. Further study is needed to validate such conclusions.
We also observed that IL-18 blockade, or absence, inhibited SDS͞SpA-induced AD. This finding suggests the importance of IL-18 as a therapeutic target molecule for certain atopic diseases.
Methods
Mice. NC͞Nga, BALB͞c, and C57BL͞6 mice were purchased from Oriental Yeast (Osaka). il18 Ϫ/Ϫ BALB͞c mice have been described elsewhere (21) . Five to seven female mice, 6-10 weeks of age, were used in each in vivo study as experimental and control groups. All mice were kept under SPF conditions and received humane care, as outlined in the Guide for the Care and Use of Laboratory Animals (36) .
Reagents. SpA from S. aureus Cowan I was purchased from Calbiochem. Anti-CD28, anti-CD3, anti-CD4, and anti-MHC class II were from Pharmingen. Hybridomas producing neutralizing anti-IFN-␥ mAb (R6A2) or anti-IL-4 mAb (11B11) were from American Type Culture Collection. Neutralizing polyclonal anti-IL-18 Abs were described elsewhere (22) . Neutralizing polyclonal anti-IL-3 Abs, soluble IL-13R␣2-Fc chimera, rIL-12, and rIL-2 were from R & D Systems. Recombinant mouse IL-18 was from MBL (Nagoya, Japan).
Induction of AD.
Mice were treated with 4% SDS in sterile distilled water on a 5-cm 2 area of their shaven backs, and 30 min later with SpA in sterile distilled water, once a day. In some experiments, mice received anti-IL-18 (500 g), anti-IFN-␥ (500 g), soluble IL-13R␣2-Fc (100 g), or anti-IL-3 (500 g) on day 0 and every 5 days after challenge with SDS͞SpA. We used in vivo a neutralizing dose of anti-IL-3 Abs or IL-13R␣2-Fc in accordance with the supplier's instructions or on the basis of our previous study (22) . Serum, plasma, skin specimens, and axillary and cervical LNs were sampled. In some experiments, skin homogenates were prepared as described in ref. 10 . A clinical AD score was determined as described in ref. 13 .
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